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OBJECTIVES This study evaluated the safety and efficacy of atrial pacing therapies for the treatment and
prevention of atrial tachycardia (AT) or atrial fibrillation (AF) in a new dual chamber
implantable cardioverter defibrillator (ICD).
BACKGROUND Patients with an ICD may also experience AT or AF that is amenable to pace termination.
METHODS The efficacy of atrial antitachycardia pacing (ATP) therapies for atrial tachycardia or atrial
fibrillation (AT/AF) was determined in 151 patients after implantation of a GEM III AT
ICD (Medtronic Inc., Minneapolis, Minnesota). The percentage of episodes successfully
terminated was adjusted for multiple episodes per patient.
RESULTS A total of 717 of 728 (96%) episodes classified as AT or AF were judged to be appropriate
detections. By device classification, atrial ATP terminated 187 of 383 (40% adjusted) episodes
classified as AT compared with 65 of 240 episodes classified as AF (26% adjusted, p 0.013).
Atrial Ramp or Burst ATP terminated 184 of 378 episodes of AT (39% adjusted), whereas
50-Hz Burst pacing therapy terminated only 12 of 109 episodes of AT (12% adjusted) and 65 of
240 episodes of AF (26% adjusted). If efficacy was defined as termination of AT/AF within 20 s
of delivery of the pacing therapy, ATP therapies terminated 139 of 383 (32% adjusted) episodes
of AT compared with 34 of 240 episodes of AF (15% adjusted, p  0.003). Efficacy was
dependent on AT cycle length. Frequent transitions between AT and AF predicted inefficacy of
atrial ATP (p  0.001). Ventricular proarrhythmia secondary to atrial ATP was not observed.
CONCLUSIONS Atrial ATP therapies terminate many episodes of AT without ventricular proarrhythmia. The
addition of 50-Hz Burst pacing has minimal efficacy for AT/AF. (J Am Coll Cardiol 2002;
40:1653–9) © 2002 by the American College of Cardiology Foundation
Data suggest that atrial pacing may prevent atrial fibrillation
(AF) in some patients (1–4). Novel pacing therapies de-
signed to suppress the triggers for AF or to modify the
electrophysiologic substrate predisposing to AF are pres-
ently undergoing clinical investigation (3). In addition,
antitachycardia pacing (ATP) therapies are now available in
some pacemakers and implantable cardioverter defibrillators
(ICD) for termination of atrial flutter or atrial tachycardia
(AT) that might degenerate into AF (5–9).
Atrial fibrillation is a frequent comorbidity in patients
who receive an ICD (7–9). Moreover, AT occurs frequently
in patients with AF and may precede the initiation of AF
(6–9). Atrial tachycardia pacing therapies have been re-
ported to terminate as many as 50% of episodes of AT in
patients with symptomatic bradycardia receiving pacemak-
ers or ICDs with atrial ATP therapies (5,8). The present
study evaluated the safety and efficacy of a new generation
ICD incorporating ATP therapies for the termination of
AT, novel pacing therapies for the prevention of AF, and
expanded diagnostic features to validate AF and AT detec-
tion and to quantify the frequency and duration of AF or
AT over time in the ICD population. The predictors of
atrial ATP efficacy were also evaluated.
METHODS
Study population. Patients with a history of sustained
ventricular tachycardia (VT) or ventricular fibrillation (VF)
were invited to participate in the Medtronic GEM III AT
(Model 7276, Medtronic Inc., Minneapolis, Minnesota)
clinical evaluation at 37 centers worldwide (Canada  7,
Europe  30). All patients gave written informed consent
to a protocol approved by the medical ethics committee of
the institution at which the devices were implanted.
GEM III AT characteristics. The GEM III AT ICD is a
multiprogrammable dual-chamber ICD with the ability to
detect and treat episodes of atrial and ventricular tachyar-
rhythmias. A previously described algorithm (PR logic,
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Medtronic Inc.) is used to discriminate ventricular from
supraventricular tachyarrhythmias based on the ratio and
timing of P waves with respect to R waves (7–9). Atrial
tachyarrhythmias are detected when the median atrial cycle
length is less than the programmed AT or AF detection
interval and the A:V ratio is greater than 1:1 for at least 32
ventricular beats. If the P:R pattern shows evidence of a
short-long atrial interval and a short A-V or V-A interval,
consistent with far field R-wave oversensing, that ventricu-
lar interval is not considered as evidence for AT or AF
detection. The device discriminates AT from AF based on
two programmable detection zones, which can overlap (Fig.
1). If the median atrial cycle length is in the overlap zone,
the rhythm is classified as AT if it is regular and AF if it is
irregular. An atrial tachyarrhythmia ends with the detection
of five consecutive sinus or paced beats with a normal A:V
pattern or if the median atrial cycle length falls outside of
the programmed AF and AT detection limits for 3 min.
The ICD was programmed to store information on 128
untreated and 25 treated episodes between interrogations.
Stored information consisted of: date, time, and duration of
the event, median atrial cycle length, therapy sequences and
therapy efficacy; 10 s of electrogram before therapy; marker
events and Marker Channel interval information for 120
intervals before therapy, 120 intervals before termination,
and the number of transitions between atrial tachycardia or
atrial fibrillation (AT/AF) during an episode. If the number
of treated episodes between interrogations exceeded the
device memory storage, only a count was kept of additional
episodes.
Atrial AT/AF therapies. Atrial therapies to treat AT/AF
episodes include three pacing algorithms for prevention
(6,7), three pacing therapies for termination, and high-
voltage shocks. The pacing prevention algorithms have been
described in detail elsewhere (5). Atrial ATP pacing ther-
apies included Ramp and Burst (a burst drive train
followed by two extra-stimuli delivered at programmed
decremented intervals) pacing and 50-Hz Burst pacing. The
50-Hz Burst pacing could only be programmed as a third or
subsequent therapy for AT. For AF, pacing therapies
consisted of 50-Hz Burst pacing only. The atrial ATP
therapies were programmed as outlined in Table 1. Atrial
cardioversion therapies were programmed at the discretion
of the individual physician. Ventricular therapies were
enabled in all patients.
By protocol, AF was classified by the ICD as an irregular
atrial tachyarrhythmia 1 min duration with cycle length
between 100 to 230 ms. Atrial tachycardia was classified as
a regular tachyarrhythmia 1 min duration with a cycle
length between 180 to 330 ms (Fig. 1).
The ICD system was evaluated before hospital discharge,
then one and three months after implant. All detected
tachyarrhythmias were retrieved by the programmer and
reviewed by the local investigator for appropriate classifica-
tion of detected event and outcome of therapy. All detected
AF and AT events with stored electrograms were reviewed
by one investigator (A.M.G.).
Data analysis. The rhythm (AT or AF) detected at the
time of the first atrial ATP therapy was used to classify the
episode. The number of transitions between AT/AF was
retrieved from the data logs for each episode. A therapy was
classified by the device as successful if five consecutive sinus
or atrial paced events occurred before redetection of AT/
AF. Examples of pace termination of AT and AF by Ramp
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
AT  atrial tachycardia
AT/AF  atrial tachycardia or atrial fibrillation
ATP  atrial tachycardia pacing
CI  confidence interval
ICD  implantable cardioverter defibrillator
VF  ventricular fibrillation
VT  ventricular tachycardia
Figure 1. Atrial tachycardia (AT) and atrial fibrillation (AF) detection
zones programmed in the study population. The minimum and maximum
AF detection intervals were 100 and 230 ms, respectively. The minimum
and maximum AT detection intervals were 180 and 330 ms, respectively.
The overlap zone was 180 to 230 ms.
Table 1. Programming Parameters
Parameters Programming
Atrial pacing preference On, Upper pacing rate 120 beats/min
Atrial rate stabilization On
Post mode switch
overdrive pacing
On, Rate 80 beats/min
Rate responsive pacing On
VT/VF detection On
AT/AF detection Both On
AF detection 1-min delay
AF zone 100–230 ms
AT zone 180–330 ms
At least 1 AT or AF
therapy
On:
 First atrial ATP: Ramp—minimum
of 5 pulses, A-S1 97%, minimum
4 sequences
 Second atrial ATP: Burst—minimum
of 15 pulses, A-S1 94%, S1-S2 91%,
S2-S3 10 ms, minimum 3 sequences
 Third atrial ATP 50-Hz Burst
(physician discretion)
A-S1  pacing interval of first ramp pulse–% of pre-therapy AT/AF interval; AF 
atrial fibrillation; AT  atrial tachycardia; ATP  atrial tachycardia pacing; S1-S2 
pacing interval of the first extra-stimulus as a % of pretherapy AT/AF interval;
S2-S3  interval decrement between S1-S2 interval and second extra-stimulus;
VF  ventricular fibrillation; VT  ventricular tachycardia.
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and 50-Hz Burst therapies are shown in Figure 2. A
primary termination was defined as immediate restoration
of sinus- or atrial-paced rhythm after ATP therapy (Fig. 1,
upper panel). A secondary termination was defined as a
transient atrial tachyarrhythmia persisting after atrial ATP
therapy (Fig. 1, lower panels). Given that many episodes of
AT/AF may terminate spontaneously, a more conservative
definition of atrial ATP therapy efficacy was also evaluat-
ed—termination of AT or AF within 20 s of delivery of the
last atrial ATP therapy. This definition of ATP efficacy was
selected based on two observations: 1) our previous study
demonstrating that when atrial ATP successfully terminated
atrial flutter or AT via a secondary termination (acceleration
to AF), the AF spontaneously terminated within 9 s of
delivery of atrial ATP (10); and 2) five consecutive sinus- or
atrial-paced beats required by the device for classification of
termination requires 6 to 11 s (based on review of episodes
in the study population).
The SAS System statistical software was used for data
analysis. Continuous data were reported as mean  1 SD.
Atrial ATP efficacy was expressed as the incidence of
successful terminations with 95% confidence intervals. The
Generalized Estimating Equations method was used to
account for the correlated data that arises from utilizing
multiple episodes in some patients (11). All efficacy esti-
mates reported are the adjusted estimates. Univariate pre-
dictors of AT/AF development and atrial ATP efficacy were
determined. Regression analysis was applied to determine
independent predictors of AT/AF development and the
efficacy of atrial pacing therapies. Differences were signifi-
cant if p  0.05.
RESULTS
The patient demographics are shown in Table 2. Patients
were followed for 79  41 days. Patients were predomi-
nantly male with left ventricular dysfunction in the setting
of coronary artery disease. Most patients had a prior history
of AT/AF.
Ventricular tachyarrhythmia detection and therapy. The
device classified 546 episodes in 47 patients as VT (n 450)
or VF (n  96). The investigators confirmed that 493
Figure 2. Examples of atrial tachycardia pacing. (A) A ramp pacing therapy terminates atrial tachycardia with immediate restoration of atrial-paced rhythm.
This episode is classified as a primary termination. The upper tracing shows atrial and ventricular electrograms. The lower tracing illustrates the marker
channel annotations and intervals between sensed or paced events. (B) Device-based atrial fibrillation terminates within 2.6 s of delivery of a 50-Hz Burst
train. The format is similar to A. AP  atrial-paced event; AR  atrial-sensed event in the refractory period; AS  atrial-sensed event; FD  fibrillation
detected; TD  tachycardia detection; TS  tachycardia-sensed; VP  ventricular-paced event; VS  ventricular-sensed event.
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episodes (90%) were VT or VF. The adjusted positive
predictive value of VT and VF detection was 0.80 (95%
confidence interval [CI], 0.67 to 0.89). The VT and VF
therapies were successful in 99% of episodes.
Detection of AT/AF. Intermittent undersensing of persis-
tent AF occurred in two patients. Episodes were censored
from data analysis when undersensing occurred during the
episode. Episodes of paroxysmal AT/AF with stored atrial
electrograms (n  728) occurred in 43 patients. Eleven
episodes (1.5%) in two patients were inappropriately classi-
fied as AT or AF by the device due to far field R-wave
oversensing. Thus, the positive predictive value of AT/AF
detection was 0.96 (95% CI, 0.84 to 0.99). This low
occurrence of inappropriate detection due to far field
R-wave oversensing was observed despite the presence of far
field R-wave oversensing before onset in 6.5% (48/728) of
device-classified AT/AF episodes.
Atrial ATP therapies. A total of 4,315 spontaneous epi-
sodes of AT or AF were detected by the device, and atrial
ATP therapies were delivered for 623 of these episodes.
Most episodes did not include an intracardiac electrogram.
A total of 36% of episodes were 1 min in duration, 40%
were 1 to 10 min in duration, and 2% were greater than 24 h
in duration. Internal atrial cardioversion was only utilized
twice by the investigators after implantation, for induced
episodes.
Primary terminations occurred in 27 of 623 (4%) treated
episodes. A primary termination of device-classified AT or
AF was observed for only one treatment with 50-Hz Burst.
The efficacy of the atrial ATP therapies based on device
classification of termination are shown in Figure 3, solid
squares. Atrial ATP successfully terminated 187 of 383
(40% adjusted) episodes classified as AT compared with 65
of 240 (26% adjusted) episodes classified as AF (p 0.013).
The overall efficacy for termination of device-classified AT
or AF was 35% adjusted. The efficacy of atrial ATP
therapies defined as termination of AT/AF within 20 s of
delivery of the last therapy is shown in Figure 3, solid circles.
Atrial ATP terminated 32% of AT episodes compared with
15% of device-classified AF episodes (p  0.003), and the
overall efficacy was 26% (adjusted efficacy rates).
Atrial tachycardia pacing efficacy was dependent on the
cycle length of the atrial tachyarrhythmia as shown in Figure
4 (odds ratio, 1.009; 95% CI, 1.003 to 1.016). For every 50
ms increase in cycle length of AT episodes treated by Ramp
or Burst, the odds of effective termination increased by
59%.
Ramp and Burst versus 50-Hz Burst pacing. The
efficacy of Ramp or Burst ATP and 50-Hz Burst pacing
are shown in Figure 5. By device classification of efficacy,
Table 2. Patient Demographics
Number 151
Male 125 (83%)
Age (yrs) 62  13
Follow-up period (days) 79  41
Primary indication for ICD
Cardiac arrest 65 (43%)
Ventricular tachycardia 121 (80%)
NSVT 20 (13%)
Heart disease
Coronary artery disease 99 (66%)
Prior myocardial infarction 96 (64%)
Cardiomyopathy 77 (51%)
Valvular 24 (16%)
Hypertension 64 (42%)
Congenital 5 (3%)
None 2 (1%)
LVEF 38  16
Prior history of AT/AF 78 (52%)
AF  atrial fibrillation; AT  atrial tachycardia; ICD  implantable cardioverter
defibrillator; LVEF  left ventricular ejection fraction; NSVT  nonsustained
ventricular tachycardia.
Figure 3. Efficacy of atrial tachycardia (AT) pacing (ATP). Data show
efficacy rates with 95% confidence intervals for spontaneous episodes of
device-classified AT, atrial fibrillation (AF), or all episodes of AT/AF. The
arrhythmia classification was based on the arrhythmia type at the time of
delivery of first ATP therapy. The efficacy rates were adjusted for multiple
events in patients using the Generalized Estimating Equations method.
Solid square  episode termination based on device classification of
efficacy; solid circle  episode termination defined as termination within
20 s of delivery of the last ATP therapy.
Figure 4. Efficacy of Ramp or Burst atrial tachycardia (AT) pacing
(ATP) therapies based on cycle length of the AT at the time of detection
(odds ratio, 1.009; 95% confidence interval, 1.003 to 1.016; p  0.004).
Episodes were grouped in quartiles. For every 50 ms increase in cycle
length of AT, the odds of effective termination increased by 59%. Solid
square  episode termination based on device classification of efficacy;
solid circle  episode termination defined as termination within 20 s of
delivery of the last pacing therapy. AF  atrial fibrillation.
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Ramp or Burst ATP therapies successfully terminated 184
of 378 episodes of AT (39% adjusted), whereas 50-Hz Burst
pacing successfully terminated only 12 of 109 episodes of
AT (12% adjusted, p 0.001). Indeed, 50-Hz Burst pacing
had minimal efficacy (12% of all episodes starting as
device-classified AF or AT) if a successful termination was
defined as restoration of sinus or atrial paced rhythm within
20 s of delivery of the last ATP therapy.
Predictors of AF and AT development and response to
therapy. Logistic regression analysis identified a prior his-
tory of AT/AF as the only predictor of AT/AF occurrence
after ICD implantation (odds ratio, 11.7; 95% CI 4.2 to
32.1; p  0.001). Regression analysis identified a prior
history of VT (odds ratio, 5.18; 95% CI, 1.36 to 19.67; p 
0.016) and the use of angiotensin-converting enzyme
(ACE) inhibitors (odds ratio, 4.07; 95% CI, 1.47 to 11.25;
p  0.01) as predictors of atrial ATP efficacy. Frequent
transitions between AT and device-classified AF during a
tachyarrhythmia episode predicted failure of ATP therapy
(odds ratio, 0.26; 95% CI, 0.19 to 0.37; p  0.001). This
analysis was based on termination of AT/AF within 20 s of
delivery of the last therapy.
DISCUSSION
The present study confirms the observations of previous
studies that AT occurs frequently in patients with a history
of AF in association with VT and VF (8–10). Furthermore,
AT is frequently terminated by atrial ATP therapies (6,9).
The present study provides new insights into the definition
of atrial ATP efficacy as well as the predictors of ATP
efficacy. In addition, the data analysis suggests that 50-Hz
Burst pacing therapy has minimal efficacy for termination of
AT or device-classified AF.
Atrial ATP efficacy. It has been hypothesized that pace
termination of AT may prevent the development of AF or
reduce overall AF burden (3,7,12). At present, long-term
studies confirming the benefit of atrial ATP therapies for
the prevention of AF are unavailable. In the present study,
using a device-based classification of arrhythmia termina-
tion, atrial ATP therapies terminated 40% of AT and 26%
of device-classified AF. In the present study, the atrial ATP
efficacy rate for AT was lower than that reported by other
investigators (5,8). By protocol, the definition of AF was
more conservative, and, hence, more episodes were classified
and treated as AT. Faster episodes of AT, some of which
may have been AF, were less likely to be terminated by ATP
therapies.
The utility of device-based arrhythmia diagnostics de-
pends directly on the accuracy of arrhythmia detection.
Analysis of stored AT/AF episodes from the present study
indicated a positive predictive value for device-classified
AT/AF detection of 0.96. Application of sophisticated
detection algorithms in the present study led to a very low
incidence of inappropriate AT/AF detection due to far field
R-wave oversensing, thus making device-based diagnostic
information more reliable.
Atrial ATP therapies have been reported to terminate
many episodes of paroxysmal AT or atrial flutter in the
pacemaker and ICD patient populations (5–9). However,
atrial ATP may accelerate atrial flutter or AT to AF before
termination (10,13). It has been thought that the creation of
a more “disorganized” atrial arrhythmia might predispose to
spontaneous termination of this secondary arrhythmia. The
time frame for resumption of sinus rhythm after the
induction of AF has been reported to be variable. We have
previously reported that atrial ATP therapies delivered by
intracardiac stimulation terminated 73% of episodes of atrial
flutter (10). Transient AF was induced in 68% of patients
during the application of ATP therapies, but the longest
episode lasted only 9 s. Other investigators have also
observed a high incidence of transient AF during pace
termination of atrial flutter that lasted as long as 24 h (13).
Because the present study population experienced frequent
paroxysmal AT/AF with many episodes spontaneously ter-
minating within 1 min of onset, a more conservative
definition of atrial ATP efficacy seems appropriate. By
design, the GEM III AT defines termination of AT/AF by
ATP as efficacious if sinus- or atrial-paced rhythm occurs
before redetection of AT/AF. Although this redetection
time is variable, the device allows up to 3 min from the last
therapy for redetection to occur. Efficacy defined as termi-
nation of AT or device-based AF within 20 s of delivery of
atrial pacing therapy seems more appropriate because we
Figure 5. Upper: Efficacy of Ramp and Burst atrial tachycardia (AT)
pacing (ATP). Data show efficacy rates with 95% confidence intervals for
spontaneous episodes of device-classified AT, atrial fibrillation (AF), or all
episodes of AT/AF. The arrhythmia classification was based on the
arrhythmia type at the time of delivery of first ATP therapy. The efficacy
rates were adjusted for multiple events in patients using the Generalized
Estimating Equation. Lower: Efficacy of 50-Hz Burst ATP. Data show
efficacy rates with 95% confidence intervals for spontaneous episodes of
device-classified AT, AF, or all episodes of AT/AF. The arrhythmia
classification was based on the arrhythmia type at the time of delivery of
first ATP therapy. The efficacy rates were adjusted for multiple events in
patients using the Generalized Estimating Equation. The 50-Hz Burst
pacing was less efficacious compared with Ramp and Burst ATP. Solid
square  episode termination based on device classification of efficacy;
solid circle  episode termination defined as termination within 20 s of
delivery of the last pacing therapy.
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have previously demonstrated that the longest episode of
transient AF during pace termination of atrial flutter was 9 s
(10), and between 6 to 11 s are required for the device to
recognize restoration of sinus- or atrial-paced rhythm. This
more conservative definition indicates that atrial ATP
efficacy is lower than previously reported. In the present
study, applying this conservative definition, atrial ATP
terminated 26% of all atrial tachyarrhythmias and 32% of
AT episodes. Transitions between device-classified AT and
AF have been observed in some patients. Although a local
atrial electrogram may appear very organized, less organized
arrhythmias may be observed in other parts of the atria (14).
This might explain why not all episodes classified by the
device as AT are effectively pace-terminated.
50-Hz Burst pacing. Previous investigators have demon-
strated that an excitable gap exists in patients with AF and
that atrial overdrive pacing may capture local areas of the
myocardium (15,16). However, local stimulation of atrial
muscle did not terminate AF. Some investigators have
suggested that rapid atrial pacing with 50-Hz Bursts might
terminate AF. More recent clinical data has not supported
this concept (17,18) although 50 Hz Burst pacing has been
found to be marginally effective for termination of rapid
atrial flutter (18). When ATP efficacy is defined as termi-
nation of device-classified AT or AF within 20 s of delivery
of ATP therapy, 50-Hz Burst pacing terminated 4% of the
episodes classified by the device as AT and 15% of episodes
classified as AF. Some episodes classified as AF could have
been rapid atrial flutter. The higher efficacy rates for 50-Hz
Burst pacing reported using the device classification of
efficacy in the present study, and other studies likely reflect
spontaneous terminations of AT/AF. Primary terminations
of device-classified AT or AF with 50-Hz Burst pacing
were rare, further supporting the concept that many epi-
sodes terminating after delivery of this therapy reflect
spontaneous terminations.
It cannot be concluded that 50-Hz Burst pacing was less
efficacious for AT compared with other ATP therapies
because this therapy was only delivered after unsuccessful
Ramp or Burst therapies for AT. However, the incremen-
tal benefit of 50-Hz Burst pacing for AT after the delivery
of Ramp or Burst ATP therapies is small.
Predictors of atrial ATP efficacy. Consistent with previ-
ous reports, atrial ATP therapies were more effective for
episodes classified as AT on the onset of therapy (8). Ramp
and Burst therapies were also more effective for tachycar-
dias with longer cycle lengths. Atrial tachycardia pacing
efficacy rates increased substantially for every 50-ms increase
in the AT cycle length. Frequent transitions between
device-classified AT and AF were associated with therapy
failure. Whether this reflects that unsuccessful episodes
were longer and, therefore, more transitions in rate and
regularity occurred, or whether this identifies an arrhythmia
characteristic that is unresponsive to ATP, is uncertain.
Israel et al. (6) have also reported that more organized ATs
are likely to be pace-terminated compared with less orga-
nized arrhythmias (6). In addition, the use of ACE inhib-
itors was predictive of atrial ATP efficacy. Angiotensin-
converting enzyme inhibitors have been reported to reduce
the magnitude of atrial fibrosis in experimental models of
AF (19). Whether this effect modulates the electrophysi-
ologic substrate to increase ATP efficacy requires further
study.
Implications for programming atrial ATP. Many epi-
sodes of AF last 1 min in duration. Other investigators
have reported that most episodes of AT remain stable over
this time frame (6). Hence, a 1-min delay before delivery of
ATP therapy would avoid unnecessary therapy for short
episodes and reduce the probability of inducing sustained
AF. Arrhythmias that frequently transition between device-
classified AT and AF are less responsive to ATP therapy,
and programming ATP therapies over the long term may
not be beneficial in such patients. Atrial 50-Hz Burst pacing
has minimal efficacy in addition to Ramp and Burst ATP
therapies. The programming parameters summarized in
Table 1 could be considered as initial programming param-
eters for patients receiving this ICD.
Ventricular therapies. The VT and VF detection and
therapy efficacies are similar to those reported for other
ICDs. Importantly, there was no evidence of ventricular
proarrhythmia secondary to atrial ATP therapies.
Study limitations. The present study was not designed to
evaluate the efficacy of the pacing prevention therapies.
Follow-up was relatively short, and it is possible that ATP
efficacies may change over time. In addition, review of the
AT episodes not treated in most cases was not possible due
to the lack of intracardiac electrograms. It is possible that
some atrial ATP therapies converted AT to AF. It was not
possible to assess this outcome in the present study. It is
possible that some episodes of AT/AF were not detected
due to intermittent undersensing.
Conclusions. Atrial tachycardia occurs frequently in pa-
tients with AF and VT. Atrial ATP therapies safely
terminate many episodes of AT although efficacy rates are
lower than previously reported. Atrial 50 Hz Burst pacing
has minimal incremental benefit compared with Ramp or
Burst therapies for AT and minimal efficacy for the
termination of device-classified AF.
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